1 King William Street

London EC4N 7AF

hello@gbx-events.com

Tel:  0203-858-8185

Fax: 0203-858-8188

  • GBX Events
  • Gbx Events (Summit) You Tube
  • Gbx Events (Summit) Twitter

© 2019 by GBX. Proudly created with GBX Events Ltd.
Company Number: 11782795 - VAT: 317674779 UK

Cell & Gene Therapy Innovation Speakers 

Ohad Karnieli

Founder and CEO

Adva Biotechnology

Dr. Karnieli earned his PhD in Biotechnology from the Sacler school of Medicine at Tel Aviv University and an MBA from the Haifa University school of management.

Lior Raviv

Vice President Development

Pluristem Therapeutics

Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Development.

André G. Gerth

Chief Executive Officer

BioPlanta GmbH

André acts as Chief executive Officer Director of BioPlanta GmbH and FamiCord Deutschland GmbH.

Magdalena Tary-Lehmann

Chief Scientific Officer

Cellular Technology Limited

Magdalena is a Co-Founding Scientist and Chief Scientific Officer for CTL and Adjunct Associate Professor of Case Western Reserve University Department of Pathology.

Alain Vertès

Managing Director

NxR Biotechnologies GmbH

Dr. Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland

Pamela Tranter

Head, Translational Research Group

UCL

Pamela joined UCL Translational Research Office (TRO) in 2014 and has been leading the Translational Research group since 2016.

Houria Bachtarzi

Senior Consultant in Gene and Cell Therapies

NDA Group AB

Dr Houria Bachtarzi is a Senior Consultant, Regulatory Affairs - Gene and Cell Therapies, with a strong scientific and regulatory experience in the field of advanced biological therapies

Otto-Wilhelm MERTEN

Gene Therapy and Vector Manufacturing Specialist

Miltenyi Biotec SAS

Otto-Wilhelm MERTEN has a degree in biotechnology (Ph.D.) from the University of Life Sciences in Vienna, holds an HDR at the University of Evry/Val-d’Essonne and is Visiting Professor at ITQB/UNL.

Marina Feschenko

Director, Analytical Development for Gene Therapy

Biogen

Dr. Marina Feschenko is currently a Principle Scientist at Biogen.

Darrin Disley

Chief Executive Officer

Mogrify Ltd

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started or invested in over 40 start-up life science, technology and social enterprises

Kyle Grant

Associate Director of Vector Production

Voyager

I am a classically trained chemical engineer with a deep understanding of molecular biology.

Paula Maria M. Alves

CEO

IBET

Paula M Alves holds a PhD in Biochemical Engineering from Instituto de Tecnologia Química Biológica da Universidade Nova de Lisboa.

Mio Muelthaler

Director, Business Development, Europe

Berkeley Lights

Mio Muelthaler is on a mission to spread the news about a new fascinating disruptive nanofluidics based single-cell technology for gene therapy in EU.

Annie Hubert

Senior Director of European Public Policy

Alliance for Regenerative Medicine

Annie brings over 30 years of experience in European regulatory and government affairs, pricing, reimbursement and market access to the ARM Team.

Shibashish Giri

Deputy Head, Applied Stem Cell Biology and Cell Technology 

University of Leipzig

Dr. Shibashish Giri has more than 12 years’ experience in preclinical research and clinical therapy for cell, tissue and organ regeneration in Germany.

Michael Kapinsky

Strategic Marketing Manager

Beckman Coulter Life Sciences

Michael Kapinsky is a chemist by training.

Sarah Snykers

QC Manager

Celyad

Sarah joined Celyad in 2015 to be at the offspring of a new exciting technology in the immunooncology field.

Christian van den Bos

Managing Director

Mares Ltd

Dr. van den Bos current developed technology and IP dramatically enhancing the efficacy of mesenchymal stem cells, the productivity of cell culture media for primary cells and a novel drug target

Laura Sepp-Lorenzino

Chief Scientific Officer

Intellia Therapeutics

Laura Sepp-Lorenzino, Ph.D. is Chief Scientific Officer of Intellia Therapeutics. In this role, she oversees all drug research across in vivo and ex vivo (engineered cell therapy) areas.

Marc Van Dijk

Vice President Platform Technology

AgenTus Therapeutics Ltd

Marc van Dijk, Ph.D. leads platform development for AgenTus and Agenus, and heads the Agenus UK site.

Maria Papathanasiou

Research Associate

Imperial College London

Dr Maria Papathanasiou is an appointed Lecturer at the Department of Chemical Engineering, Imperial College London (in effect April 2020).

Eric Halioua

President & Chief Executive Officer

PDC*line Pharma

Mr. Eric Halioua, MS, MBA, serves as President of the Board, Chief Executive Officer and President of PDC line Pharma SAS.

Jennifer murray

Managing Director/Past Chair

Life Science Group Ltd/International Serum Industry Association

Jenny has over 30 years’ experience in the cell culture industry in the UK and worldwide and a track record in building successful SMCs. Jenny is the current owner of Life Science Group Ltd (LSG).

Cell & Gene Therapy Innovation Past Speakers